AbbVie Inc.’s latest foray into CAR-T cell therapy is a partnership with Umoja Biopharma, Inc. focused on in vivo CAR-T cells, an area a number of companies large and small have explored with mixed results, but could help overcome the manufacturing bottlenecks that have been a limitation for autologous CAR-Ts.
AbbVie Looks To Umoja To Partner On In Vivo CAR-Ts
Umoja Also Signs Deal With IASO Bio
Umoja’s technology is meant to enable development of CAR-Ts that could potentially overcome the challenges associated with autologous cell therapies, especially related to manufacturing.
